Search

Your search keyword '"Dubray Longeras, P."' showing total 117 results
Start Over Author "Dubray Longeras, P."
117 results on '"Dubray Longeras, P."'

1. Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial

Author

Passildas Jahanmohan Judith, Bernadach Maureen, Pouget Mélanie, Kwiatkowski Fabrice, Vanpraagh‐Doreau Isabelle, Dubray‐Longeras Pascale, Abrial Catherine, Nabholtz Jean‐Marc, Curé Hervé, Delecroix Valérie, Chollet Philippe, and Mouret‐Reynier Marie‐Ange

Subjects
advanced and metastatic breast cancer, chemotherapy, curcumin, docetaxel, phytotherapy, Medicine
Abstract

Abstract Background In this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line treatment potentiated the objective response rate. Patients/Methods A multicentre, randomized, open label, phase‐II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel‐curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time‐to‐progression, progression‐free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy. Results In this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time‐to‐progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression‐free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance (p = 0.14). Conclusion In this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second‐line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.

Published
2024
Full Text
View/download PDF

2. Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma

Author

Dufresne, A., Pokras, S., Meurgey, A., Chabaud, S., Toulmonde, M., Bompas, E., Le Cesne, A., Robin, Y.-M., Duffaud, F., Valentin, T., El Zein, S., Leroux, A., Dubray-Longeras, P., Firmin, N., de Pinieux, G., Noal, S., Delfour, C., Bollard, J., Tonon, L., Biette, A., Gadot, N., Attignon, V., Jean-Denis, M., Woessner, M., Klohe, E., Thayaparan, T., Eleftheriadou, I., Blouch, K., Nathenson, M.J., and Blay, J.-Y.

Published
2024
Full Text
View/download PDF

3. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author

Kubicek, Pierre, Cesne, Axel Le, Lervat, Cyril, Toulmonde, Maud, Chevreau, Christine, Duffaud, Florence, Le Nail, Louis-Romée, Morelle, Magali, Gaspar, Nathalie, Vérité, Cécile, Castex, Marie-Pierre, Penel, Nicolas, Saada, Esma, Causeret, Sylvain, Bertucci, François, Perrin, Christophe, Bompas, Emmanuelle, Orbach, Daniel, Laurence, Valérie, Piperno-Neumann, Sophie, Anract, Philippe, Rios, Maria, Gentet, Jean-Claude, Mascard, Éric, Pannier, Stéphanie, Blouin, Pascale, Carrère, Sébastien, Chaigneau, Loïc, Soibinet-Oudot, Pauline, Corradini, Nadège, Boudou-Rouquette, Pascaline, Ruzic, Jean-Christophe, Lebrun-Ly, Valérie, Dubray-Longeras, Pascale, Varatharajah, Sharmini, Lebbe, Céleste, Ropars, Mickaël, Kurtz, Jean-Emmanuel, Guillemet, Cécile, Lotz, Jean-Pierre, Berchoud, Juliane, Cherrier, Grégory, Ducimetière, Françoise, Chemin, Claire, Italiano, Antoine, Honoré, Charles, Desandes, Emmanuel, Blay, Jean-Yves, Gouin, François, and Marec-Bérard, Perrine

Published
2023
Full Text
View/download PDF

4. Improved nationwide survival of sarcoma patients with a network of reference centers

Author

Blay, J.Y., Penel, N., Valentin, T., Anract, P., Duffaud, F., Dufresne, A., Verret, B., Cordoba, A., Italiano, A., Brahmi, M., Henon, C., Amouyel, T., Ray-Coquard, I., Ferron, G., Boudou-Rouquette, P., Tlemsani, C., Salas, S., Rochwerger, R., Faron, M., Bompas, E., Ducassou, A., Gangloff, D., Gouin, F., Firmin, N., Piperno-Neumann, S., Rios, M., Ropars, M., Kurtz, J.E., Le Nail, L.R., Bertucci, F., Carrere, S., Llacer, C., Watson, S., Bonvalot, S., Leroux, A., Perrin, C., Gantzer, J., Pracht, M., Narciso, B., Monneur, A., Lebbe, C., Hervieu, A., Saada-Bouzid, E., Dubray-Longeras, P., Fiorenza, F., Chaigneau, L., Nevieres, Z.-M., Soibinet, P., Bouché, O., Guillemet, C., Spano, J.P., Ruzic, J.C., Isambert, N., Vaz, G., Meeus, P., Karanian, M., Ngo, C., Coindre, J.M., De Pinieux, G., Le Loarer, F., Ducimetiere, F., Chemin, C., Morelle, M., Toulmonde, M., and Le Cesne, A.

Published
2024
Full Text
View/download PDF

5. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

Author

Blay, JY, Tlemsani, C., Toulmonde, M., Italiano, A., Rios, M., Bompas, E., Valentin, T., Duffaud, F., Le Nail, LR, Watson, S., Firmin, N., Dubray-Longeras, P., Ropars, M., Perrin, C., Hervieu, A., Lebbe, C., Saada-Bouzid, E., Soibinet, P., Fiorenza, F., Bertucci, F., Boudou, P., Vaz, G., Bonvalot, S., Honoré, C., Marec-Berard, P., Minard, V., Cleirec, M., Biau, D., Meeus, P., Babinet, A., Dumaine, V., Carriere, S., Fau, M., Decanter, G., Gouin, F., Ngo, C., Le Loarer, F., Karanian, M., Meurgey, A., Dufresne, A., Brahmi, M., Chemin-Airiau, C., Ducimetiere, F., Penel, N., and Le Cesne, A.

Published
2024
Full Text
View/download PDF

6. The efficacy of immune checkpoint inhibitors following discontinuation for long‐term response or toxicity in advanced or metastatic non‐small‐cell lung cancers: A retrospective study

Author

Laure Vacher, Maureen Bernadach, Ioana Molnar, Judith Passildas‐Jahanmohan, and Pascale Dubray‐Longeras

Subjects
immune‐related adverse events, immunotherapy, long‐term response, metastatic non‐small‐cell lung cancer, nivolumab, pembrolizumab, Medicine
Abstract

Abstract Background and Aims The treatment of metastatic non‐small‐cell lung cancer (NSCLC) has been revolutionized by the arrival of immune checkpoint inhibitors (ICI). For patients without immune related adverse events (irAEs), it is recommended to continue the treatment as long as it provides clinical benefit or until unacceptable toxicity appears. The aim of our study was to evaluate survival data among patients with advanced or metastatic NSCLC following ICI discontinuation for reasons of long‐term response or toxicity (irAEs). Methods We included all patients with advanced or metastatic NSCLC treated with nivolumab and pembrolizumab at the Centre Jean Perrin, Clermont‐Ferrand, France (January 1, 2016 to May 31, 2019). We focused on two groups in this study population: “Voluntary treatment discontinuation” (medical decision as a result of long‐term response and patient decision) and “Treatment discontinuation due to toxicity” (irAEs). The primary endpoint was to evaluate the postdiscontinuation outcomes of these two groups: progression‐free survival (PFS) and overall survival (OS), and rechallenge in the “voluntary discontinuation” group. Results The final analysis concerned 146 patients, including 10 (7%) in the “discontinuation due to toxicity” group, 11 (8%) in the “voluntary discontinuation” group, 100 (68%) who discontinued treatment as a result of progression and 25 (17%) whose treatment was still on‐going. The median PFS in the “discontinuation due to toxicity” group was not reached, and in the “voluntary discontinuation” group (n = 11) was 37 months (p = 0.4), versus 2 months in the progression group (p

Published
2024
Full Text
View/download PDF

7. Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years

Author

Blay, JY, Piperno-Neumann, S., Watson, S., Dufresne, A., Valentin, T., Duffaud, F., Toulmonde, M., Italiano, A., Bertucci, F., Tlemsani, C., Firmin, N., Bompas, E., Perrin, C., Ropars, M., Saada-Bouzid, E., Dubray-Longeras, P., Hervieu, A., Lebbe, C., Gantzer, J., Chaigneau, L., Fiorenza, F., Rios, M., Isambert, N., Soibinet, P., Boudou-Roquette, P., Verret, B., Ferron, G., Ryckewaert, T., Lebellec, L., Brahmi, M., Gouin, F., Meeus, P., Vaz, G., Le Loarer, F., Karanian, M., De Pinieux, G., Ducimetiere, F., Chemin, C., Morelle, M., Le Cesne, A., and Penel, N.

Published
2023
Full Text
View/download PDF

8. Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author

Pierre Kubicek, Axel Le Cesne, Cyril Lervat, Maud Toulmonde, Christine Chevreau, Florence Duffaud, Louis-Romée Le Nail, Magali Morelle, Nathalie Gaspar, Cécile Vérité, Marie-Pierre Castex, Nicolas Penel, Esma Saada, Sylvain Causeret, François Bertucci, Christophe Perrin, Emmanuelle Bompas, Daniel Orbach, Valérie Laurence, Sophie Piperno-Neumann, Philippe Anract, Maria Rios, Jean-Claude Gentet, Éric Mascard, Stéphanie Pannier, Pascale Blouin, Sébastien Carrère, Loïc Chaigneau, Pauline Soibinet-Oudot, Nadège Corradini, Pascaline Boudou-Rouquette, Jean-Christophe Ruzic, Valérie Lebrun-Ly, Pascale Dubray-Longeras, Sharmini Varatharajah, Céleste Lebbe, Mickaël Ropars, Jean-Emmanuel Kurtz, Cécile Guillemet, Jean-Pierre Lotz, Juliane Berchoud, Grégory Cherrier, Françoise Ducimetière, Claire Chemin, Antoine Italiano, Charles Honoré, Emmanuel Desandes, Jean-Yves Blay, François Gouin, and Perrine Marec-Bérard

Subjects
Adolescents and young adults, AYAs, Sarcoma, Management, Multidisciplinary tumor board, Reference centers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. Patients and methods NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15–30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Results Among 3,227 patients aged 15–30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p

Published
2023
Full Text
View/download PDF

9. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

Author

Moreau-Bachelard, C., Campion, L., Toulmonde, M., Le Cesne, A., Brahmi, M., Italiano, A., Mir, O., Piperno-Neumann, S., Laurence, V., Firmin, N., Penel, N., Duffaud, F., Chevreau, C., Bertucci, F., Narciso, B., Dubray-Longeras, P., Delcambre, C., Saada-Bouzid, E., Boudou-Rouquette, P., Soulie, P., Perrin, C., Blay, J.Y., and Bompas, E.

Published
2022
Full Text
View/download PDF

10. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

Author

Chouaid, Christos, Filleron, Thomas, Debieuvre, Didier, Pérol, Maurice, Girard, Nicolas, Dansin, Eric, Lena, Hervé, Gervais, Radj, Cousin, Sophie, Otto, Josiane, Schott, Roland, Planchard, David, Madroszyk, Anne, Kaderbhai, Courèche, DUBRAY-Longeras, Pascale, Hiret, Sandrine, Pichon, Eric, Clément-Duchêne, Christelle, Chenuc, Gaëlle, Simon, Gaëtane, Bosquet, Lise, and QUantin, Xavier

Published
2021
Full Text
View/download PDF

11. Determinants of the access to remote specialised services provided by national sarcoma reference centres

Author

Yohan Fayet, Raphaël Tétreau, Charles Honoré, Louis-Romée Le Nail, Cécile Dalban, François Gouin, Sylvain Causeret, Sophie Piperno-Neumann, Simone Mathoulin-Pelissier, Marie Karanian, Antoine Italiano, Loïc Chaigneau, Justine Gantzer, François Bertucci, Mickael Ropars, Esma Saada-Bouzid, Abel Cordoba, Jean-Christophe Ruzic, Sharmini Varatharajah, Françoise Ducimetière, Sylvie Chabaud, Pascale Dubray-Longeras, Fabrice Fiorenza, Sixtine De Percin, Céleste Lebbé, Pauline Soibinet, Paul Michelin, Maria Rios, Fadila Farsi, Nicolas Penel, Emmanuelle Bompas, Florence Duffaud, Christine Chevreau, Axel Le Cesne, Jean-Yves Blay, François Le Loarer, and Isabelle Ray-Coquard

Subjects
Cancer inequalities, Spatial inequalities, Reference networks, Sarcoma, Cancer care accessibility, Rare cancers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national reference network implemented to improve the outcome of sarcoma patients in France since 2010, providing remote access to specialized diagnosis and Multidisciplinary Tumour Board (MTB). The IGéAS research program aims to assess the potential of this innovative organization, with remote management of cancers including rare tumours, to go through geographical barriers usually impeding the optimal management of cancer patients. Methods Using the nationwide NETSARC+ databases, the individual, clinical and geographical determinants of the access to sarcoma-specialized diagnosis and MTB were analysed. The IGéAS cohort (n = 20,590) includes all patients living in France with first sarcoma diagnosis between 2011 and 2014. Early access was defined as specialised review performed before 30 days of sampling and as first sarcoma MTB discussion performed before the first surgery. Results Some clinical populations are at highest risk of initial management without access to sarcoma specialized services, such as patients with non-GIST visceral sarcoma for diagnosis [OR 1.96, 95% CI 1.78 to 2.15] and MTB discussion [OR 3.56, 95% CI 3.16 to 4.01]. Social deprivation of the municipality is not associated with early access on NETSARC+ remote services. The quintile of patients furthest away from reference centres have lower chances of early access to specialized diagnosis [OR 1.18, 95% CI 1.06 to 1.31] and MTB discussion [OR 1.24, 95% CI 1.10 to 1.40] but this influence of the distance is slight in comparison with clinical factors and previous studies on the access to cancer-specialized facilities. Conclusions In the context of national organization driven by reference network, distance to reference centres slightly alters the early access to sarcoma specialized services and social deprivation has no impact on it. The reference networks’ organization, designed to improve the access to specialized services and the quality of cancer management, can be considered as an interesting device to reduce social and spatial inequalities in cancer management. The potential of this organization must be confirmed by further studies, including survival analysis.

Published
2021
Full Text
View/download PDF

12. Determinants of the access to remote specialised services provided by national sarcoma reference centres

Author

Fayet, Yohan, Tétreau, Raphaël, Honoré, Charles, Le Nail, Louis-Romée, Dalban, Cécile, Gouin, François, Causeret, Sylvain, Piperno-Neumann, Sophie, Mathoulin-Pelissier, Simone, Karanian, Marie, Italiano, Antoine, Chaigneau, Loïc, Gantzer, Justine, Bertucci, François, Ropars, Mickael, Saada-Bouzid, Esma, Cordoba, Abel, Ruzic, Jean-Christophe, Varatharajah, Sharmini, Ducimetière, Françoise, Chabaud, Sylvie, Dubray-Longeras, Pascale, Fiorenza, Fabrice, De Percin, Sixtine, Lebbé, Céleste, Soibinet, Pauline, Michelin, Paul, Rios, Maria, Farsi, Fadila, Penel, Nicolas, Bompas, Emmanuelle, Duffaud, Florence, Chevreau, Christine, Le Cesne, Axel, Blay, Jean-Yves, Le Loarer, François, and Ray-Coquard, Isabelle

Published
2021
Full Text
View/download PDF

14. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

Author

Blay, JY, primary, Tlemsani, C., additional, Toulmonde, M, additional, Italiano, A., additional, Rios, M., additional, Bompas, E., additional, Valentin, T., additional, Duffaud, F., additional, Le Nail, LR, additional, Watson, S., additional, Firmin, N, additional, Dubray-Longeras, P, additional, Ropars, M, additional, Perrin, C., additional, Hervieu, A, additional, Lebbe, C, additional, Saada-Bouzid, E, additional, Soibinet, P., additional, Fiorenza, F., additional, Bertucci, F., additional, Boudou, P., additional, Vaz, G, additional, Bonvalot, S., additional, Honoré, C., additional, Marec-Berard, P, additional, Minard, V., additional, Cleirec, M., additional, Biau, D., additional, Meeus, P, additional, Babinet, A., additional, Dumaine, V., additional, Carriere, S., additional, Fau, M., additional, Decanter, G, additional, Gouin, F., additional, Ngo, C., additional, Le Loarer, F., additional, Karanian, M., additional, Meurgey, A, additional, Dufresne, A., additional, Brahmi, M., additional, Chemin-Airiau, C., additional, Ducimetiere, F., additional, Penel, N., additional, and Le Cesne, A., additional

Published
2023
Full Text
View/download PDF

15. Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate

Author

Decanter, Gauthier, Stoeckle, Eberhard, Honore, Charles, Meeus, Pierre, Mattei, Jean Camille, Dubray-Longeras, Pascale, Ferron, Gwenael, Carrere, Sébastien, Causeret, Sylvain, Guilloit, Jean-Marc, Fau, Magali, Rosset, Philippe, Machiavello, Jean-Christophe, Delhorme, Jean Baptiste, Regenet, Nicolas, Gouin, François, Blay, Jean-Yves, Coindre, Jean-Michel, Penel, Nicolas, and Bonvalot, Sylvie

Published
2019
Full Text
View/download PDF

16. Improved survival using specialized multidisciplinary board in sarcoma patients

Author

Blay, J.-Y., Soibinet, P., Penel, N., Bompas, E., Duffaud, F., Stoeckle, E., Mir, O., Adam, J., Chevreau, C., Bonvalot, S., Rios, M., Kerbrat, P., Cupissol, D., Anract, P., Gouin, F., Kurtz, J. -E., Lebbe, C., Isambert, N., Bertucci, F., Toumonde, M., Thyss, A., Piperno-Neumann, S., Dubray-Longeras, P., Meeus, P., Ducimetière, F., Giraud, A., Coindre, J. -M., Ray-Coquard, I., Italiano, A., and Le Cesne, A.

Published
2017
Full Text
View/download PDF

17. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Author

Salas, S., Resseguier, N., Blay, J.Y., Le Cesne, A., Italiano, A., Chevreau, C., Rosset, P., Isambert, N., Soulie, P., Cupissol, D., Delcambre, C., Bay, J.O., Dubray-Longeras, P., Krengli, M., De Bari, B., Villa, S., Kaanders, J.H.A.M., Torrente, S., Pasquier, D., Thariat, J.O., Myroslav, L., Sole, C.V., Dincbas, H.F., Habboush, J.Y., Zilli, T., Dragan, T., Khanfir, K., Ugurluer, G., Cena, T., Duffaud, F., Penel, N., Bertucci, F., Ranchere-Vince, D., Terrier, P., Bonvalot, S., Macagno, N., Lemoine, C., Lae, M., Coindre, J.M., and Bouvier, C.

Published
2017
Full Text
View/download PDF

18. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Author

Nabholtz, J.M., Abrial, C., Mouret-Reynier, M.A., Dauplat, M.M., Weber, B., Gligorov, J., Forest, A.M., Tredan, O., Vanlemmens, L., Petit, T., Guiu, S., Van Praagh, I., Jouannaud, C., Dubray-Longeras, P., Tubiana-Mathieu, N., Benmammar, K.E., Kullab, S., Bahadoor, M.R.K., Radosevic-Robin, N., Kwiatkowski, F., Desrichard, A., Cayre, A., Uhrhammer, N., Chalabi, N., Chollet, P., and Penault-Llorca, F.

Published
2014
Full Text
View/download PDF

20. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC)

Author

Cabart, M., primary, Mourey, L., additional, Girard, N., additional, Otto, J., additional, Gervais, R., additional, Madroszyk, A., additional, Chouaid, C., additional, Dubray-Longeras, P., additional, Pérol, M., additional, Hiret, S., additional, Kaderbhai, C., additional, Pichon, E., additional, Debieuvre, D., additional, Baranzelli, A., additional, Schneider, S., additional, Schott, R., additional, Pasquier, D., additional, Simon, G., additional, Martin, A.L., additional, and Cabarrou, B., additional

Published
2021
Full Text
View/download PDF

21. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

Author

Cabart, Mathilde, Mourey, Loïc, Pasquier, David, Schneider, Sophie, Léna, Hervé, Girard, Nicolas, Chouaid, Christos, Schott, Roland, Hiret, Sandrine, Debieuvre, Didier, Quantin, Xavier, Madroszyk, Anne, Dubray-Longeras, Pascale, Pichon, Eric, Baranzelli, Anne, Justeau, Grégoire, Pérol, Maurice, Bosquet, Lise, and Cabarrou, Bastien

Abstract

In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical Economics (ESME) platform on Lung Cancer (LC), the objective is to provide an overview of the management and the prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC) in a real-world context. From the ESME-LC database, we selected patients with AM-NSCLC (stage IIIB, IIIC, and IV), diagnosed between 2015 and 2019, and who received first-line systemic treatment. Demographics, tumour characteristics, and treatment received were described in patients ≥70, and compared to younger ones. Real-world progression-free survival (rwPFS) and overall survival (OS) were evaluated using the multivariable Cox model. Among 10,002 patients with AM-NSCLC, the median age was 64 years, with 2,754 (27.5%) aged ≥70. In comparison with patients <70, older patients were more often male, with worse performance status and more comorbidities, but they were less underweight and more often non-smokers. The proportion of EGFR mutated non-squamous NSCLC was higher in older patients (25.0% vs 12.8%, p < 0.001), particularly among smokers and former smokers (12.7% vs 7.3%, p < 0.001). Among patients ≥70, 76.6% received first-line chemotherapy (including 67.0% treated with a platinum-based doublet), 15.0% received only targeted therapy, and 11.0% received immunotherapy (alone or in combination). Median first-line rwPFS was 5.1 months (95% confidence interval [CI] = [4.8;5.4]) for patients ≥70 and 4.6 months (95%CI = [4.4;4.8]) for patients <70, but age was not associated with rwPFS in multivariable analysis. Median OS was 14.8 months (95%CI = [13.9;16.1]) for patients ≥70 and 16.7 months (95%CI = [15.9;17.5]) for patients <70, with a significant effect of age in multivariable analysis for patients treated with chemotherapy and/or with targeted therapy, but not for patients treated with immunotherapy (alone or in combination with chemotherapy). In this real-world cohort of patients with AM-NSCLC, age was not associated with first-line rwPFS regardless of treatment received, nor with OS for patients receiving immunotherapy. However, OS was significantly shorter for patients aged ≥70 treated with chemotherapy or with targeted therapy alone. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. 1530P Outcome of primary soft tissue or bone myoepithelial tumors (METs)

Author

Cavaillon, S., primary, Toulmonde, M., additional, Wallet, J., additional, Robin, Y.M., additional, Honoré, C., additional, Duffaud, F., additional, Anract, P., additional, Rosset, P., additional, Carrere, S., additional, Lebbe, C., additional, Bompas, E., additional, Dubray-Longeras, P., additional, Bertucci, F., additional, Gantzer, J., additional, Chevreau, C.M., additional, Mesli, N., additional, Courreges, J-B., additional, Chemin-Airiau, C., additional, Dufresne, A., additional, and Penel, N., additional

Published
2021
Full Text
View/download PDF

23. 822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy

Author

Ray-Coquard, I.L., primary, Bompas, E., additional, Cropet, C., additional, Donnat, M., additional, Bertucci, F., additional, Chaigneau, L., additional, Metzger, S., additional, Dufresne, A., additional, Guillemet, C., additional, Pacaut Vassal, C., additional, Vénat-Bouvet, L., additional, Vegas, H., additional, Piperno-Neumann, S., additional, Fabbro, M., additional, Blay, J-Y., additional, Dubray-Longeras, P., additional, Savoye, A.M., additional, Brahmi, M., additional, and Floquet, A., additional

Published
2021
Full Text
View/download PDF

24. Exploratory analyses of surrogate endpoints in metastatic non-small cell lung cancer

Author

Bouteiller, F., primary, Cousin, S., additional, Sofeu, C., additional, Perrocheau, G., additional, Gervais, R., additional, Perol, M., additional, Girard, N., additional, Chamorey, E., additional, Pasquier, D., additional, Dubray Longeras, P., additional, Kaderbhai, C., additional, Schott, R., additional, Filleron, T., additional, Chouaid, C., additional, Debieuvre, D., additional, Valette, C. Audigier, additional, Quantin, X., additional, Bosquet, L., additional, Martin, A., additional, and Bellera, C., additional

Published
2021
Full Text
View/download PDF

25. 1928P Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010

Author

Blay, J-Y., Rouquette, P. Boudou, Toulmonde, M., Italiano, A., Penel, N., Rios, M., Gouin, F., Valentin, T., Duffaud, F., Le Nail, L.R., Watson, S., Firmin, N., Dubray-Longeras, P., Ropars, M., Hervieu, A., Fiorenza, F., Lebbe, C., Saada, E.B., Oudot, P. Soibinet, and Le Cesne, A.

Published
2023
Full Text
View/download PDF

28. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique

Author

Girard, N., primary, Filleron, T., additional, Pérol, M., additional, Chouaid, C., additional, Debieuvre, D., additional, Quantin, X., additional, Dayen, C., additional, Lena, H., additional, Schott, R., additional, Gervais, R., additional, Schneider, S., additional, Otto, J., additional, Dansin, E., additional, Dubray Longeras, P., additional, Kaderbhai, C., additional, Madroszyk, A., additional, Clément-Duchêne, C., additional, Pichon, E., additional, Planchard, D., additional, Lemoine, A., additional, Bizieux, A., additional, Baranzelli, A., additional, Cousin, S., additional, Couch, D., additional, Hominal, S., additional, Thureau, S., additional, Le Treut, J., additional, Robain, M., additional, Hiret, S., additional, Simon, G., additional, and Audigier-Vallette, C., additional

Published
2021
Full Text
View/download PDF

29. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France

Author

Pérol, M., primary, Carton, M., additional, Debieuvre, D., additional, Quantin, X., additional, Girard, N., additional, Audigier-Vallette, C., additional, Lena, H., additional, Filleron, T., additional, Schott, R., additional, Gervais, R., additional, Hiret, S., additional, Otto, J., additional, Dansin, E., additional, Dubray Longeras, P., additional, Kaderbhai, C., additional, Madroszyk, A., additional, Clément-Duchêne, C., additional, Pichon, E., additional, Planchard, D., additional, Lemoine, A., additional, Thureau, S., additional, Baranzelli, A., additional, Cousin, S., additional, Schneider, S., additional, Bizieux, A., additional, Le Treut, J., additional, Hominal, S., additional, Dayen, C., additional, Simon, G., additional, Robain, M., additional, Couch, D., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

30. Efficacité et tolérance du lorlatinib en 2e ligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

Author

Baldacci, S., primary, Besse, B., additional, Avrillon, V., additional, Mennecier, B., additional, Dubray-Longeras, P., additional, Mazières, J., additional, Descourt, R., additional, Duruisseaux, M., additional, Quantin, X., additional, Doubre, H., additional, Monnet, I., additional, Moro-Sibilot, D., additional, Schneider, S., additional, Cousin, S., additional, Merle, P., additional, Otto, J., additional, Langlais, A., additional, Morin, F., additional, Westeel, V., additional, and Girard, N., additional

Published
2021
Full Text
View/download PDF

31. 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

Author

Nishio, M., primary, Barlesi, F., additional, Ball, S., additional, Bordoni, R., additional, Cobo, M., additional, Dubray-Longeras, P., additional, Goldschmidt, J., additional, Novello, S., additional, Orlandi, F.J., additional, Sanborn, R., additional, Szalai, Z., additional, Ursol, G., additional, Mendus, D., additional, Wang, L., additional, Wen, X., additional, McCleland, M., additional, Hoang, T., additional, Phan, S., additional, and Socinski, M., additional

Published
2020
Full Text
View/download PDF

32. 1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO)

Author

Moreau-Bachelard, C., primary, Toulmonde, M., additional, Le Cesne, A., additional, Brahmi, M., additional, Italiano, A., additional, Mir, O., additional, Piperno-Neumann, S., additional, Laurence, V., additional, Firmin, N., additional, Chevreau, C.M., additional, Bertucci, F., additional, Narciso, B., additional, Dubray-Longeras, P., additional, Delcambre, C., additional, Saada-Bouzid, E., additional, Soulié, P., additional, Perrin, C., additional, Blay, J-Y., additional, and Bompas, E., additional

Published
2020
Full Text
View/download PDF

33. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Author

Baldacci, S., primary, Besse, B., additional, Avrillon, V., additional, Mennecier, B., additional, Dubray-Longeras, P., additional, Mazieres, J., additional, Descourt, R., additional, Duruisseaux, M., additional, Quantin, X., additional, Doubre, H., additional, Monnet, I., additional, Moro-Sibilot, D., additional, Schneider, S., additional, Cousin, S., additional, Merle, P., additional, Otto, J., additional, Langlais, A., additional, Morin, F., additional, Westeel, V., additional, and Girard, N., additional

Published
2020
Full Text
View/download PDF

35. Prise en charge des patients atteints d’un cancer bronchopulmonaire à petites cellules de stade IV – Analyse de la base nationale de données de vie réelle du programme Épidémio-Stratégie Médico-Économique (ESME)

Author

Audigier-Valette, C., Filleron, T., Debieuvre, D., Kaderbhai, C., Lena, H., Cousin, S., Gervais, R., Schott, R., Otto, J., Dubray Longeras, P., Girard, N., Pérol, M., Chouaid, C., Pichon, E., Hominal, S., Madroszyk, A., Lemoine, A., Hiret, S., Schneider, S., Dansin, E., Planchard, D., Baranzelli, A., Bizieux, A., Clément-Duchêne, C., Le Treut, J., Dayen, C., Couch, D., Thureau, S., Robain, M., Simon, G., and Quantin, X.

Published
2021
Full Text
View/download PDF

36. OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Author

Papadimitrakopoulou, V., primary, Cobo, M., additional, Bordoni, R., additional, Dubray-Longeras, P., additional, Szalai, Z., additional, Ursol, G., additional, Novello, S., additional, Orlandi, F., additional, Ball, S., additional, Goldschmidt, J., additional, Sanborn, R., additional, Hoang, T., additional, Mendus, D., additional, Deng, Y., additional, Kowanetz, M., additional, Wen, X., additional, Lin, W., additional, Sandler, A., additional, and Nishio, M., additional

Published
2018
Full Text
View/download PDF

37. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a Compassionate Use Programme in France

Author

Young, Jacques, primary, Bertherat, Jérôme, additional, Vantyghem, Marie Christine, additional, Chabre, Olivier, additional, Senoussi, Salima, additional, Chadarevian, Rita, additional, Castinetti, Frédéric, additional, _, _, additional, Abeillon, J, additional, Ajzenberg, C, additional, Andrieu, J-M, additional, Arbey, A-S, additional, Archambeaud, F, additional, Arnault, G, additional, Bacchetta, J, additional, Baechler-Sadoul, E, additional, Bakiri, F, additional, Batisse-Lignier, M, additional, Baudry, C, additional, Benamo, E, additional, Bennet, A, additional, Berdelou, A, additional, Bertherat, J, additional, Boehna, A, additional, Borson-Chazot, F, additional, Bourcigaux, N, additional, Bourquard, C, additional, Bouys, L, additional, Bremont-Weill, C, additional, Bricaire, L, additional, Brue, T, additional, Buliga, D, additional, Cabaret, P, additional, Caron, P, additional, Cerro-Martinez, M, additional, Chambre, C, additional, Chardonnet, M, additional, Chatelin, J, additional, Clavel, C, additional, Coffin, C, additional, Cohen, R, additional, Collet-Gaudillat, C, additional, Cortet, C, additional, Coulon, A-L, additional, De Boisvilliers, F, additional, Decker-Bellaton, A, additional, Delemer, B, additional, De Menthon, M, additional, Degros, V, additional, Deneuville, T, additional, Desailloud, R, additional, Di Pietro, G, additional, Do Cao, C, additional, Donadille, B, additional, Dolz, M, additional, Dubray-Longeras, P, additional, Dutertre, E, additional, Du Rostu, H, additional, El Farkh, J, additional, Faure, G, additional, Finichel, P, additional, Gaits, N, additional, Galland, F, additional, Genc, S, additional, Ghanassia, E, additional, Girard, J-J, additional, Gravis, G, additional, Groza, L, additional, Grunenberger, F, additional, Guiheneuf, C, additional, Guignat, L, additional, Guigui, M, additional, Guilhem, A, additional, Joubert, M, additional, Jublanc, C, additional, Kamenicky, P, additional, Kerlan, V, additional, Khalfallah, Y, additional, Lambrey, G, additional, Landau, E, additional, Lautridou, C, additional, Lefebvre, H, additional, Le Bras, M, additional, Le Guillou, A-C, additional, Le Pommelet, C, additional, Léonard, F, additional, Lin, L, additional, Luca, F, additional, Lunogo, C, additional, Maisin, A, additional, Maiza, J-C, additional, Marty, M, additional, Meliani, P, additional, Menon, S, additional, Mestre, B, additional, Mignot, B, additional, Millot, S, additional, Morange, I, additional, Moret, M, additional, Morlet-Barla, N, additional, Narbonne, H, additional, Néraud, B, additional, Néri, N, additional, Niccoli, P, additional, Nunes, M L, additional, Oudard, S, additional, Papadopoulou, S, additional, Petit, J-M, additional, Petit-Aubert, G, additional, Perrin, A, additional, Philippon, M, additional, Pillegrand, C, additional, Potton, L, additional, Raverot, G, additional, Rodes, M L, additional, Reznik, Y, additional, Sadoul, J L, additional, Salenave, S, additional, Saraval-Gross, M, additional, Sarfati, J, additional, Savel, J, additional, Schletzer, M A, additional, Schneebeli, S, additional, Schillo, F, additional, Smagala, A, additional, Sonnet, E, additional, Teissier, R, additional, Tessier, M P, additional, Trulli, F, additional, Vackrine, C, additional, Vezzosi, D, additional, Viard, A, additional, Villeneuve, A, additional, Weryha, G, additional, and Zalzali, M, additional

Published
2018
Full Text
View/download PDF

38. The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment

Author

Blay, J.-Y., primary, Le Cesne, A., additional, Penel, N., additional, Bompas, E., additional, Chevreau, C., additional, Duffaud, F., additional, Rios, M., additional, Kerbrat, P., additional, Cupissol, D., additional, Anract, P., additional, Kurtz, J.-E., additional, Lebbe, C., additional, Bertucci, F., additional, Piperno-Neumann, S., additional, Rosset, P., additional, Isambert, N., additional, Dubray-Longeras, P., additional, Ducimetière, F., additional, Coindre, J.-M., additional, and Italiano, A., additional

Published
2016
Full Text
View/download PDF

39. Everolimus Plus Hormonotherapy (Ht) Induces Survival Gain in Late Metastatic Breast Cancer (Mbc) After Progression: Could this Line Be Better Than a Late New Chemotherapy (Ct) Line?

Author

Pouget, M., primary, Planchat, E., additional, Abrial, C., additional, van Praagh, I., additional, Arbre, M., additional, Kwiatkowski, F., additional, Dubray-Longeras, P., additional, Devaud, H., additional, Wang-Lopez, Q., additional, Mahammedi, H., additional, Durando, X., additional, Chollet, P., additional, and Mouret-Reynier, M., additional

Published
2014
Full Text
View/download PDF

40. Abstract P1-08-34: Is it possible to predict the efficacy of a combination of cetuximab plus docetaxel in patients with operable, triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial

Author

Nabholtz, J-M, primary, Mouret-Reynier, M-A, additional, Abrial, C, additional, Dauplat, M-M, additional, Radosevic-Robin, N, additional, Van Praagh, I, additional, Servent, V, additional, Jacquin, J-P, additional, Bourcier, A-V, additional, Del Piano, F, additional, Dubray-Longeras, P, additional, Nayl, B, additional, Kwiatkoswki, F, additional, Cayre, A, additional, Uhrhammer, N, additional, Bidet, Y, additional, Chalabi, N, additional, Bignon, Y-J, additional, Chollet, P, additional, and Penault-Llorca, F, additional

Published
2013
Full Text
View/download PDF

41. 1397O - The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment

Author

Blay, J.-Y., Le Cesne, A., Penel, N., Bompas, E., Chevreau, C., Duffaud, F., Rios, M., Kerbrat, P., Cupissol, D., Anract, P., Kurtz, J.-E., Lebbe, C., Bertucci, F., Piperno-Neumann, S., Rosset, P., Isambert, N., Dubray-Longeras, P., Ducimetière, F., Coindre, J.-M., and Italiano, A.

Published
2016
Full Text
View/download PDF

42. Survie globale (SG) et survie sans rechute (SSR) dans différents sous-groupes de cancers du sein : luminal A, luminal B, triple négatifs et Her2+, traités par chimiothérapie néoadjuvante (CTNA)

Author

Abrial, C., primary, Dauplat, M.-M., additional, Wang-Lopez, Q., additional, Mouret-Reynier, M.-A., additional, Dubray-Longeras, P., additional, Van Praagh-Doreau, I., additional, Durando, X., additional, Nabholtz, J.-M., additional, Chollet, P., additional, and Penault-Llorca, F., additional

Published
2012
Full Text
View/download PDF

43. Long-Term Overall Survival (OS) and Disease-Free Survival (DFS) According to PCR in Breast Cancers Subtypes: Luminal A and B, Triple Negative and HER2 +, Treated by Neaodjuvant Chemotherapy (NCT)

Author

Abrial, C., primary, Wang-Lopez, Q., additional, Mouret-Reynier, M., additional, Dubray-Longeras, P., additional, van Praagh-Doreau, I., additional, Durando, X., additional, Gimbergues, P., additional, Nabholtz, J., additional, Penault-Llorca, F., additional, and Chollet, P., additional

Published
2012
Full Text
View/download PDF

44. Représentations croisées sur l’alimentation et la dénutrition chez les patients atteints de cancer : résultats de l’étude NutriCancer2012

Author

Raynard, Bruno, Hébuterne, Xavier, Goldwasser, François, Ait Hssain, Ali, Dubray Longeras, Pascale, Barthélémy, Philippe, Rosso, Edoardo, Phoutthasang, Valérie, Bories, Camille, Digue, Laurence, Laharie, David, Desport, Jean-Claude, Falkowski, Sabrina, Lacau Saint Guily, Jean, and Gyan, Emmanuel

Abstract

La dénutrition est fréquente en cancérologie. Cependant, elle est souvent détectée tardivement et sa prise en charge n’est pas toujours optimale. L’avis du patient, bien que souvent sollicité dans les décisions thérapeutiques en oncologie, ne semble pas fréquemment pris en compte dans le domaine nutritionnel. Dans le cadre de l’étude NutriCancer2012, nous avons interrogé les patients, les proches et les médecins sur leur perception de l’impact de la dénutrition et de la qualité de sa prise en charge. Parmi les 2209 patients interrogés, la majorité se disait concernée par la problématique nutritionnelle avec 75 % qui considéraient indispensable une prise en charge nutritionnelle adaptée mais seulement 19 % faisaient le lien entre dénutrition et fatigue. Les médecins sous-estimaient l’impact ressenti (par les patients) de la dénutrition sur leur « qualité de vie ». Les médecins évoquaient le manque de moyens humains et de connaissance en nutrition et étaient plus de 80 % à solliciter la création d’unités transversales de nutrition. Une sensibilisation du grand public, des patients et des proches dès le diagnostic de cancer pourrait favoriser le dépistage de la dénutrition. Une meilleure formation en nutrition des médecins et la création d’unités transversales de nutrition pourraient optimiser la prise en charge et en améliorer l’efficacité au cours des traitements anticancéreux.

Published
2017
Full Text
View/download PDF

45. P3-14-01: Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.

Author

Nabholtz, J-M, primary, Weber, B, additional, Gligorov, J, additional, Mouret-Reynier, M-A, additional, Tredan, O, additional, Vanlemmens, L, additional, Petit, T, additional, Mayer, F, additional, Van, Praagh-Doreau I, additional, Dubray-Longeras, P, additional, Nayl, B, additional, Ferriere, J-P, additional, Jouannaud, C, additional, Devaud, H, additional, Tubiana-Mathieu, N, additional, Abrial, C, additional, Kwiatkowski, F, additional, Planchat, E, additional, Chalabi, N, additional, Penault-Llorca, F, additional, and Chollet, P, additional

Published
2011
Full Text
View/download PDF

46. Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.

Author

Nabholtz, J., primary, Weber, B., additional, Mouret-Reynier, M., additional, Gligorov, J., additional, Coudert, B. P., additional, Vanlemmens, L., additional, Petit, T., additional, Tredan, O., additional, Van Praagh-Doreau, I., additional, Dubray-Longeras, P., additional, Ferriere, J., additional, Nayl, B., additional, Tubiana-Mathieu, N., additional, Jouannaud, C., additional, Devaud, H., additional, Abrial, C., additional, Planchat, E., additional, Chalabi, N., additional, Penault-Llorca, F. M., additional, and Chollet, P. J. M., additional

Published
2011
Full Text
View/download PDF

47. What is the survival length from the late lines of treatment in metastatic breast cancer?

Author

Mouret-Reynier, M., primary, Planchat, E., additional, Thivat, E., additional, Abrial, C., additional, Pomel, C., additional, Dubray-Longeras, P., additional, Devaud, H., additional, Nayl, B., additional, Dillies, A., additional, Wang-Lopez, Q., additional, Chollet, P. J. M., additional, Cure, H., additional, Nabholtz, J., additional, and Durando, X., additional

Published
2011
Full Text
View/download PDF

49. Efficacité et tolérance du lorlatinib en 2eligne ou plus chez les patients, porteurs d’un cancer bronchique non à petites cellules (CBNPC) avancé ALK+, traités dans le cadre d’une autorisation temporaire d’utilisation (ATU), étude IFCT-1803 LORLATU

Author

Baldacci, S., Besse, B., Avrillon, V., Mennecier, B., Dubray-Longeras, P., Mazières, J., Descourt, R., Duruisseaux, M., Quantin, X., Doubre, H., Monnet, I., Moro-Sibilot, D., Schneider, S., Cousin, S., Merle, P., Otto, J., Langlais, A., Morin, F., Westeel, V., and Girard, N.

Abstract

Le lorlatinib est un inhibiteur de tyrosine kinase (ITK) de troisième génération ciblant ALK et ROS1 disponible en France depuis octobre 2015 via une ATU pour les CBNPC avancés ALK+ après échec d’au moins un ITK ALK. Les données concernant l’efficacité et la tolérance du lorlatinib utilisé dans cette indication sont encore parcellaires et reposent sur les Résultats d’un seul essai de phase II.

Published
2021
Full Text
View/download PDF

50. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial

Author

Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin‐Broto, Antonio Lopez‐Pousa, Giovanni Grignani, Antonella Brunello, Jean‐Yves Blay, Oscar Tendero, Robert Diaz‐Beveridge, Virginia Ferraresi, Iwona Lugowska, Gabriele Infante, Luca Braglia, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Giuseppe Bianchi, Andrea Marrari, Carlo Morosi, Silvia Stacchiotti, Silvia Bagué, Jean Michel Coindre, Angelo Paolo Dei Tos, Piero Picci, Paolo Bruzzi, Rosalba Miceli, Paolo Giovanni Casali, Alessandro Gronchi, Carla Dani, Chiara Villa, Antonella Messina, Lorella Rusi, Anna Maria Nuzzo, Carmen Nuzzo, Antonino De Paoli, Angela Buonadonna, Alessandro Comandone, Antonella Boglione, Lorenzo Livi, Daniela Greto, Nada Riva, Manuela Monti, Elisabetta Pennacchioli, Tommaso De Pas, Vincenzo Ippolito, Patrico Ledesma, Andres Redondo, Claudia Valverde, Raquel Bratos, Josefina Cruz, Javier Martinez Trufero, Ricardo Cubedo, Isabel Sevilla, Pablo Luna, Rafael Lopez, Pilar Sancho, Olivia Bally, Mehdi Brahmi, Isabelle Ray‐Coquard, Philippe Cassier, Nathalie Marques, Luis Tassy, Pascaline Boudou‐Rouquette, Camille Tlemsani, Jerome Alexandre, Francois Goldwasser, Emmanuelle Bompas, Frederic Rolland, Christophe Perrin, Marie Talarmin, Antoine Italiano, Maud Toulmonde, Mathieu Laramas, Jacques‐Olivier Bay, Pascale Dubray‐Longeras, Piotr Rutkowski, PharmaMar, European Commission, Pasquali, Sandro, Palmerini, Emanuela, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Stacchiotti, Silvia, Pasquali S., Palmerini E., Quagliuolo V., Martin-Broto J., Lopez-Pousa A., Grignani G., Brunello A., Blay J.-Y., Tendero O., Diaz-Beveridge R., Ferraresi V., Lugowska I., Infante G., Braglia L., Merlo D.F., Fontana V., Marchesi E., Donati D.M., Palassini E., Bianchi G., Marrari A., Morosi C., Stacchiotti S., Bague S., Coindre J.M., Dei Tos A.P., Picci P., Bruzzi P., Miceli R., Casali P.G., Gronchi A., Dani C., Villa C., Messina A., Rusi L., Nuzzo A.M., Nuzzo C., De Paoli A., Buonadonna A., Comandone A., Boglione A., Livi L., Greto D., Riva N., Monti M., Pennacchioli E., De Pas T., Ippolito V., Ledesma P., Redondo A., Valverde C., Bratos R., Cruz J., Martinez Trufero J., Cubedo R., Sevilla I., Luna P., Lopez R., Sancho P., Bally O., Brahmi M., Ray-Coquard I., Cassier P., Marques N., Tassy L., Boudou-Rouquette P., Tlemsani C., Alexandre J., Goldwasser F., Bompas E., Rolland F., Perrin C., Talarmin M., Italiano A., Toulmonde M., Laramas M., Bay J.-O., Dubray-Longeras P., and Rutkowski P.

Subjects
Oncology, Adult, Cancer Research, medicine.medical_specialty, sarcoma, Anthracycline, medicine.medical_treatment, Soft Tissue Neoplasms, Lower risk, chemotherapy, Risk Assessment, nomogram, Interquartile range, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Ifosfamide, Chemotherapy, business.industry, Soft tissue sarcoma, neoadjuvant, clinical trial, Nomogram, medicine.disease, Neoadjuvant Therapy, Chemotherapy, Adjuvant, chemotherapy, clinical trial, neoadjuvant, nomogram, sarcoma, Sarcoma, business, medicine.drug
Abstract

[Background] The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS., [Methods] This study analyzed data from ISG-STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology-tailored (HT) chemotherapy in adult patients with STS. The 10-year predicted overall survival (pr-OS) was estimated with the Sarculator and was stratified into higher (10-year pr-OS < 60%) and lower risk subgroups (10-year pr-OS ≥ 60%)., [Results] The median pr-OS was 0.63 (interquartile range [IQR], 0.51-0.72) for the entire study population, 0.62 (IQR, 0.51-0.70) for the AI arm, and 0.64 (IQR, 0.51-0.73) for the HT arm. Three- and 5-year overall survival (OS) were 0.86 (95% confidence interval [CI], 0.82-0.93) and 0.81 (95% CI, 0.71-0.86) in lower risk patients and 0.69 (95% CI, 0.70-0.85) and 0.59 (95% CI, 0.51-0.72) in the higher risk patients (log-rank test, P = .004). In higher risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.68 and 0.58, respectively, and 0.85 and 0.66, respectively, in the AI arm (P = .04); the corresponding figures in the HT arm were 0.69 and 0.60, respectively, and 0.69 and 0.55, respectively (P > .99). In lower risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.85 and 0.80, respectively, and 0.89 and 0.82, respectively, in the AI arm (P = .507); the corresponding figures in the HT arm were 0.87 and 0.81, respectively, and 0.86 and 0.74, respectively (P = .105)., [Conclusions] High-risk patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS., This was a nonfunded analysis. In the ISG-STS 1001 trial, PharmaMar provided trabectedin for the HG-MRLPS cohort. That trial was partially funded through a European Union grant (EUROSARC FP7 278472).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results